Ascendis Pharma A/S $ASND Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP decreased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 30.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,548,636 shares of the biotechnology company’s stock after selling 679,997 shares during the period. Wellington Management Group LLP owned about 2.48% of Ascendis Pharma A/S worth $413,052,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ASND. Nomura Asset Management Co. Ltd. lifted its stake in shares of Ascendis Pharma A/S by 57.5% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 43,701 shares of the biotechnology company’s stock worth $9,319,000 after acquiring an additional 15,950 shares in the last quarter. Candriam S.C.A. boosted its holdings in Ascendis Pharma A/S by 23.2% in the first quarter. Candriam S.C.A. now owns 230,278 shares of the biotechnology company’s stock valued at $52,671,000 after purchasing an additional 43,338 shares during the last quarter. Orbimed Advisors LLC grew its stake in Ascendis Pharma A/S by 5.8% during the 1st quarter. Orbimed Advisors LLC now owns 181,977 shares of the biotechnology company’s stock valued at $41,624,000 after purchasing an additional 10,000 shares in the last quarter. UBS Group AG grew its stake in Ascendis Pharma A/S by 57.9% during the 4th quarter. UBS Group AG now owns 308,190 shares of the biotechnology company’s stock valued at $65,718,000 after purchasing an additional 112,986 shares in the last quarter. Finally, Cormorant Asset Management LP purchased a new stake in Ascendis Pharma A/S during the 4th quarter worth approximately $21,324,000.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND opened at $247.91 on Friday. Ascendis Pharma A/S has a twelve month low of $186.05 and a twelve month high of $282.15. The company has a current ratio of 2.99, a quick ratio of 2.32 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $15.46 billion, a price-to-earnings ratio of 19.23 and a beta of 0.39. The business has a 50 day simple moving average of $255.74 and a 200-day simple moving average of $239.08.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. As a group, equities research analysts expect that Ascendis Pharma A/S will post 3.9 earnings per share for the current year.

Ascendis Pharma A/S News Roundup

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: HC Wainwright initiated coverage of Ascendis Pharma with a Buy rating and a $345 price target, implying approximately 39% potential upside from the referenced share price. The bullish stance provides positive analyst support for ASND. HC Wainwright initiates coverage
• Positive Sentiment: HC Wainwright analyst M. Kapoor projected Ascendis Pharma will earn $3.93 per share in fiscal 2026, broadly above the cited consensus estimate of $3.90, and expects quarterly EPS of $1.16 in Q3 2026 and $1.66 in Q4 2026. HC Wainwright FY2026 estimates
• Positive Sentiment: The firm forecast substantial earnings growth in 2027, with quarterly EPS estimates rising from $1.76 in Q1 to $4.42 in Q4, resulting in projected full-year EPS of $11.88. If achieved, that would represent a significant improvement over the 2026 forecast and supports the analyst’s optimistic valuation. HC Wainwright FY2027 estimates

Insider Activity

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime purchased 2,000 shares of Ascendis Pharma A/S stock in a transaction dated Friday, August 14th. The shares were bought at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the transaction, the director owned 2,900 shares in the company, valued at $714,357. This represents a 222.22% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 40.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ASND. Citigroup initiated coverage on Ascendis Pharma A/S in a research report on Monday, May 18th. They issued a “buy” rating and a $355.00 target price on the stock. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an “outperform” rating in a research report on Friday, August 14th. Barclays dropped their price target on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating for the company in a research note on Friday, August 14th. HC Wainwright initiated coverage on shares of Ascendis Pharma A/S in a research note on Thursday. They set a “buy” rating and a $345.00 price objective on the stock. Finally, Morgan Stanley increased their price objective on shares of Ascendis Pharma A/S from $256.00 to $275.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $302.68.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.